Melanoma drug combo tested in everyday practice

NCT ID NCT04961619

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well the combination of dabrafenib and trametinib works in real-life settings for people with high-risk stage III melanoma that has been completely removed by surgery. It included 39 adults in Turkey whose melanoma had a specific genetic mutation (V600E). The main goal was to see how long patients stayed cancer-free after starting treatment. This was an observational study, meaning researchers did not give the drugs but simply collected data from routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Novartis Investigative Site

Antalya, Konyaalti, 07070, Turkey (Türkiye)
Novartis Investigative Site

Edirne, Merkez, 22030, Turkey (Türkiye)
Novartis Investigative Site

Bursa, Nilufer, 16059, Turkey (Türkiye)
Novartis Investigative Site

Diyarbakır, Sur, 21280, Turkey (Türkiye)
Novartis Investigative Site

Istanbul, Uskudar, 34668, Turkey (Türkiye)
Novartis Investigative Site

Adana, Yuregir, 1230, Turkey (Türkiye)
Novartis Investigative Site

Ankara, 06520, Turkey (Türkiye)
Novartis Investigative Site

Izmir, 35100, Turkey (Türkiye)
Novartis Investigative Site

Kecioren Ankara, 06010, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.